Cargando…
A Serum Metabolomic Study Reveals Changes in Metabolites During the Treatment of Lung Cancer-Bearing Mice with Anlotinib
BACKGROUND: Anlotinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor recommended for the treatment of advanced lung cancer patients after at least two previous systemic chemotherapies. Currently, many patients with lung cancer do not respond well to anlotinib treatment. T...
Autores principales: | Pan, Xiaoting, Chen, Wenhao, Nie, Mengjun, Liu, Yuanjie, Xiao, Zuopeng, Zhang, Ying, Zhang, Wei, Zou, Xi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349534/ https://www.ncbi.nlm.nih.gov/pubmed/34377024 http://dx.doi.org/10.2147/CMAR.S300897 |
Ejemplares similares
-
A clinical study of Yiqi Huayu Jiedu decoction reducing the risk of postoperative gastric cancer recurrence and metastasis: Study protocol for a randomized controlled trail
por: Hu, Yue, et al.
Publicado: (2020) -
An Integrative Metabolomic and Network Pharmacology Study Revealing the Regulating Properties of Xihuang Pill That Improves Anlotinib Effects in Lung Cancer
por: Li, Chunyu, et al.
Publicado: (2021) -
Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature
por: Zhang, Xi, et al.
Publicado: (2021) -
Multiplatform Metabolomics Reveals Novel Serum Metabolite Biomarkers in Diabetic Retinopathy Subjects
por: Xuan, Qiuhui, et al.
Publicado: (2020) -
UHPLC-HRMS-based metabolomic and lipidomic characterization of glioma cells in response to anlotinib
por: Shi, Yingying, et al.
Publicado: (2023)